Global burden of primary liver cancer in 2020 and predictions to 2040

Rumgay, Harriet; Arnold, Melina; Ferlay, Jacques; Lesi, Olufunmilayo; Cabasag, Citadel J.; Vignat, Jérôme; Laversanne, Mathieu; McGlynn, Katherine A.; Soerjomataram, Isabelle

doi:10.1016/j.jhep.2022.08.021

Cited by 926 publications

(505 citation statements)

References 37 publications

Supporting

Mentioning

493

Contrasting

Unclassified

Order By: Relevance

“…2,3 The incidence rate of HCC is projected to increase by 55% by 2040. 4 With the substantial clinical and economic burden on patients, caregivers, and society, effective management of cirrhosis and HCC is pivotal. [5][6][7] Optimal management of cirrhosis, particularly in those with decompensated cirrhosis, may be challenging.…”

Section: Introductionmentioning

confidence: 99%

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Yeo

Samaan

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Patients with cirrhosis and hepatocellular carcinoma (HCC) require extensive care. Personalized education can improve their outcomes. ChatGPT (Generative Pre-trained Transformer), a natural language processing model, has shown potential to provide professional yet patient-freindly responses. Aim: To examine the accuracy and reproducibility of ChatGPT in responding to questions regarding knowledge, management, and emotional support for cirrhosis and HCC. Method: ChatGPT's responses to 164 frequently asked questions were independently graded by two transplant hepatologists, with a third reviewer resolving any discrepancies. We also compared the performance of ChatGPT on two previously validated and published questionnaires to the physicians or trainees who were tested in the included publications. Furthermore, we formulated the 26 quality measures of cirrhosis management into questions and tested ChatGPT's knowledge in cirrhosis care. Finally, the capacity to provide emotional support to patients or caregivers was tested. Results: ChatGPT regurgitated extensive knowledge about both cirrhosis and HCC, but for questions with correct responses, only a small proportion was labelled as comprehensive. The performance was better in basic knowledge, lifestyle, and treatment than in the domains of diagnosis and preventive medicine. For the quality measures, the model answered 76.9% of questions correctly but failed to specify the cut-off values for making medical decisions and treatment durations. When compared to physicians/trainees, ChatGPT fell short in knowledge of guidelines varying across geographic regions, such as HCC screening criteria. The model also provided practical and multifaceted advice to patients and caregivers regarding the next steps and adjusting to a new diagnosis. Conclusion: In summary, we analyzed the areas of robustness and limitations of ChatGPT's responses on the management of cirrhosis and HCC and relevant emotional support. ChatGPT may have a role as an adjunct informational tool for patients and physicians to improve outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Yeo

Samaan

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In China, the etiological composition of HCC is mainly composed of HCC with chronic HBV infection [ 16 , 17 ], so this study was conducted with HBV-related early HCC. We collected serum samples from 32 HCs, 30 CHB patients, and 51 patients with HBV-related early-stage primary HCC ( Tables S7–S9 ) and measured the expression levels of ANGPTL6 in serum by ELISA.…”

Section: Resultsmentioning

confidence: 99%

“…Chronic hepatitis B virus (HBV) infection is a major influential factor in the occurrence of HCC [ 15 ]. Especially in China, the incidence of HBV-associated HCC remains higher than that of HCC associated with other etiologies [ 16 , 17 ]. However, the mechanism of hepatocarcinogenesis is complex, and its mechanism is still not fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

Screening for Lipid-Metabolism-Related Genes and Identifying the Diagnostic Potential of ANGPTL6 for HBV-Related Early-Stage Hepatocellular Carcinoma

Zuo

Xiao

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Lipid metabolic reprogramming is one of the hallmarks of hepatocarcinogenesis and development. Therefore, lipid-metabolism-related genes may be used as potential biomarkers for hepatocellular carcinoma (HCC). This study aimed to screen for genes with dysregulated expression related to lipid metabolism in HCC and explored the clinical value of these genes. We screened differentially expressed proteins between tumorous and adjacent nontumorous tissues of hepatitis B virus (HBV)-related HCC patients using a Nanoscale Liquid Chromatography–Tandem Mass Spectrometry platform and combined it with transcriptomic data of lipid-metabolism-related genes from the GEO and HPA databases to identify dysregulated genes that may be involved in lipid metabolic processes. The potential clinical values of these genes were explored by bioinformatics online analysis tools (GEPIA, cBioPortal, SurvivalMeth, and TIMER). The expression levels of the secreted protein (angiopoietin-like protein 6, ANGPTL6) in serum were analyzed by ELISA. The ability of serum ANGPTL6 to diagnose early HCC was assessed by ROC curves. The results showed that serum ANGPTL6 could effectively differentiate between HBV-related early HCC patients with normal serum alpha-fetoprotein (AFP) levels and the noncancer group (healthy participants and chronic hepatitis B patients) (AUC = 0.717, 95% CI: from 0.614 to 0.805). Serum ANGPTL6 can be used as a potential second-line biomarker to supplement serum AFP in the early diagnosis of HBV-related HCC.

show abstract

“…Liver cancer ranks the fourth most prevalent and the second most lethal cancer in China [1,2]. Approximately 410,000 patients were newly diagnosed with liver cancer in China in 2020(https://gco.iarc.fr), accounting for 45.3% of global new cases [3].…”

Section: Introductionmentioning

confidence: 99%

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Xie¹,

Shi²,

Zhou³

et al. 2023

Clin Mol Hepatol

View full text Add to dashboard Cite

Liver cancer ranks the fourth most prevalent and the second most lethal cancer in China.Hepatitis B virus (HBV) infection represents the major risk factor for hepatocellular carcinoma(HCC) in China. Liver US plus AFP every 6 months continues to be the predominant surveillance modality. The aMAP score is newly recommended in the 2022 Chinese guidelines to predict HCC occurrence. China liver cancer (CNLC) staging system proposed in the 2017 guideline continues to be the standard model for staging with modifications in the treatment allocations. Considering the aggressive nature of HBV-associated HCC, multi-modal and high-intensity strategies treatments like the addition of immunotherapy-based systemic treatment to local therapies including resection, ablation, intra-arterial therapies have been adopted in real-life practices in China. The latest Chinese guidelines recommend atezolizumab plus bevacizumab, suntilimab plus bevacizumab analogue, lenvatinib, sorafenib, donafenib and FOLFOX chemotherapy as the first-line treatment without priority. Apart from regorafenib, apatinib, camrelizumab and tislelizumab are newly added as the secondline systemic therapies for patients who progressed on sorafenib. Systemic therapies adopted in real life practice are sophisticated with various combination modality and different sequences.

show abstract

Global burden of primary liver cancer in 2020 and predictions to 2040

Cited by 926 publications

References 37 publications

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Screening for Lipid-Metabolism-Related Genes and Identifying the Diagnostic Potential of ANGPTL6 for HBV-Related Early-Stage Hepatocellular Carcinoma

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Contact Info

Product

Resources

About